Elevar Therapeutics

Pharma

2 FDA citations trouble Hengrui, Elevar’s liver cancer combo

Following resolution of the problem cited in the CRL, investors questioned why the FDA issued a swift rejection instead of waiting for the PDUFA date.

Angus Liu Jul 28, 2026 3:02pm

GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia

Jul 17, 2026 9:38am

FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time

Jul 10, 2026 10:55am

AZ, Boehringer-Simcere, Daiichi and more—Fierce Pharma Asia

Jan 30, 2026 7:45am

Padcev-Keytruda result, Alzheimer's med, Fosun—Fierce Pharma Asia

Aug 15, 2025 8:31am

Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia

Mar 28, 2025 9:28am